Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

TPF (docetaxel, cisplatin, fluorouracil) is the standard chemotherapy used for induction in locally advanced head and neck squamous cell carcinoma (LAHNSCC). Its toxicity limits it to younger patients with good functional status and without significant comorbidity. Since modified TPF (mTPF) demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fayette, Jérôme, Fontaine-Delaruelle, Clara, Ambrun, Alexis, Daveau, Clémentine, Poupart, Marc, Ramade, Antoine, Zrounba, Philippe, Neidhardt, Eve-Marie, Péron, Julien, Diallo, Alpha, Céruse, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095077/
https://www.ncbi.nlm.nih.gov/pubmed/27119503
http://dx.doi.org/10.18632/oncotarget.8934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095077/
https://www.ncbi.nlm.nih.gov/pubmed/27119503
http://dx.doi.org/10.18632/oncotarget.8934

Ejemplares similares